These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31039068)

  • 1. ICER Can Do Better for Patients.
    Mendez K
    J Manag Care Spec Pharm; 2019 May; 25(5):514-516. PubMed ID: 31039068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma.
    Tice JA; Campbell JD; Synnott PG; Walsh JME; Kumar VM; Whittington M; Adair E; Rind D; Pearson SD
    J Manag Care Spec Pharm; 2019 May; 25(5):510-514. PubMed ID: 31039065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric Severe Asthma in the Era of Biologic Treatments.
    Teague WG
    Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):118-120. PubMed ID: 32953228
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic Burden Associated with Receiving Inhaled Corticosteroids with Leukotriene Receptor Antagonists or Long-Acting Beta Agonists as Combination Therapy in Older Adults.
    Altawalbeh SM; Thorpe CT; Zgibor JC; Kane-Gill S; Kang Y; Thorpe JM
    J Manag Care Spec Pharm; 2018 May; 24(5):478-486. PubMed ID: 29694289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe asthma and biologics: Data are good, listening to patients is better.
    Bukstein DA; Guerra DG
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):285-286. PubMed ID: 34479728
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
    Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
    J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care.
    Price DB; Appleby JL
    Respir Med; 1998 Feb; 92(2):351-3. PubMed ID: 9616537
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?
    Anderson WC; Szefler SJ
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):367-372. PubMed ID: 30703438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma-based severity levels: Insights from a large US commercial and managed Medicaid population.
    Pollack M; Gandhi H; Tkacz J; Lanz M; Lugogo N; Gilbert I
    J Manag Care Spec Pharm; 2022 Aug; 28(8):881-891. PubMed ID: 35708342
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Biological Agents in Asthma: Pharmacoeconomic Lessons Learned From Omalizumab.
    Draikiwicz S; Oppenheimer J
    Chest; 2017 Feb; 151(2):249-251. PubMed ID: 28183482
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to Campbell, Spackman, Sullivan letter to Allergy.
    Brown R; Turk F; Dale P; Bousquet J
    Allergy; 2008 Jun; 63(6):783. PubMed ID: 18445194
    [No Abstract]   [Full Text] [Related]  

  • 14. Revisiting the cost-effectiveness of omalizumab.
    Campbell JD; Spackman DE; Sullivan SD
    Allergy; 2007 Dec; 62(12):1469. PubMed ID: 17983382
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
    Luskin AT; Antonova EN; Broder MS; Chang E; Raimundo K; Solari PG
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
    Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
    Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?
    Chapman RH; Kumar V
    J Manag Care Spec Pharm; 2019 May; 25(5):521-524. PubMed ID: 31039064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of asthma management strategies.
    Thomas M; Haughney J; Price D
    Pharmacoeconomics; 2002; 20(11):789. PubMed ID: 12201798
    [No Abstract]   [Full Text] [Related]  

  • 19. Urgent need for pragmatic trial platforms in severe asthma.
    Pilette C; Brightling C; Lacombe D; Brusselle G
    Lancet Respir Med; 2018 Aug; 6(8):581-583. PubMed ID: 30070256
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.